Novavax Inc (NASDAQ:NVAX) Stock Jumps Above $200 After The Big News
Novavax Inc (NASDAQ:NVAX) has reached an agreement with the European Commission (EC) for the purchase of up to 200M doses of NVX-CoV2373, the company’s recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-M adjuvant. The agreement covers the purchase of up to 100M doses of the vaccine with the option for an additional 100M doses through 2023. Novavax is working to complete its rolling submission for NVX-CoV2373 to the European Medicines…